Select Language
Free Registration

AIDD-Ready Core Product Portfolio
Essential Resources for AI Drug Screening & Validation

  • Affinity-Validated Target Proteins
  • Challenging-Target Proteins & Functional Cell Lines IP Friendly
  • TR-FRET Solutions

Faced with the large number of antibody candidates generated by AI, efficient screening requires reliable, ready-to-use antigens. ACRO offers recombinant proteins covering a broad range of drug targets. Validated by BLI/SPR affinity testing, these proteins can be used directly for binding and affinity screening of antibody candidates, enabling rapid Hit identification while reducing time spent on protein preparation and assay optimization—well suited to the high-throughput, fast-paced nature of AI-driven drug development.

BLI/SPR Validated, Activity Confirmed

BLI/SPR affinity testing provides real binding data to confirm protein activity, ensuring reliable performance in AI-driven antibody screening.

Broad Coverage, Screening Ready

A broad portfolio of drug targets across disease areas provides diverse antigen resources for large-scale screening of AI-generated antibody candidates.

Ready to Use, Faster Hit Discovery

Pre-validated proteins minimize protein preparation and assay optimization, enabling direct BLI/SPR screening and faster identification of promising Hits.

AIDD-Ready Core Service Platform:
CHO-Direct™

CHO-Direct™ is purpose-built for AI-driven antibody pipelines, connecting the full workflow from AI-powered design → Stage 1: high-throughput screening → Stage 2: antibody expression & purification → Stage 3: in-depth characterization → AI model iteration / preclinical development. It provides a standardized, reproducible, and iterative wet-lab framework to efficiently advance AI-designed antibodies from virtual design to preclinical development.

AIDD-Ready also includes a cell-free expression (CFS) platform for rapid production of small proteins such as VHHs and mini-proteins. With fast turnaround, CFS complements CHO-Direct™ to support wet-lab validation across diverse AI-designed molecules.

Inquire Nowicon-more
  • Stage 1: High-Throughput Screening
  • Stage 2: Antibody Expression & Purification
  • Stage 3: In-Depth Characterization

Stage 1: High-Throughput Supernatant Screening (Rapid Candidate Screening & Model Iteration)

High-throughput validation of AI-generated antibody sequences enables rapid identification of positive candidates and efficient elimination of non-performing sequences. This reduces downstream validation costs while generating the first round of experimental data to drive AI model iteration.

icon-starStandard Workflow
Automated Report Delivered in as Fast as 4 Days
  • Day 0

    AI Antibody Sequence Receipt & Analysis

  • Day 1

    Gene Synthesis & Construct Generation

  • Day 2

    CHO Cell Transfection & Expression

  • Day 3

    Supernatant Harvest & Testing

  • Day 4

    Automated Report Delivery

icon-starCore Services
Standard DeliverablesStandard Deliverables
  • icon-check
    Antibody Expression Quantification

    Assess antibody expression to rapidly identify low-expressing or abnormal sequences

  • icon-check
    BLI Affinity Ranking

    High-throughput affinity analysis with automated reporting for efficient candidate ranking

Optional AssaysOptional Assays
  • icon-check
    ELISA Binding Validation

    Confirm binding specificity and minimize false positives

  • icon-check
    Flow Cytometry Screening

    Cell-based binding screening for membrane protein targets

  • icon-check
    sELISA Epitope Binning

    Characterize antibody epitopes

  • icon-check
    Early Functional Assessment

    TR-FRET/ELISA blocking and binding assays for early assessment of candidate activity

icon-starCore Service Advantages
Efficient Screening

96-well high-throughput parallel screening rapidly eliminates low-expression and low-activity sequences, focusing efforts on high-potential candidates

Data-Driven

Rapidly generate multidimensional data on expression, binding activity, and kinetics, providing timely feedback for AI model iteration

Cost-Efficient

Eliminate the need to build an in-house high-throughput expression platform, reducing early-stage R&D costs

Inquire Nowicon-more

CHO-Direct™ Platform Equipment Showcase

AmMag™ Quatro 1300 Automated Antibody Purification System

Hamilton Microlab® STAR Automated Liquid Handling Workstation

Octet® RH96 96-Channel High-Throughput System

Biacore™ 8K Biomolecular Interaction Analysis System

BMG LABTECH Multimode Microplate Reader

Uncle Biologics Stability Screening Platform

CHO-Direct™ One-Stop Antibody Screening & Validation Service

Starting from AI-designed antibody sequences, CHO-Direct™ provides one-stop wet-lab validation covering high-throughput expression, functional activity, and developability assessment.

Inquire Nowicon-more
Share to:

Join UsLegalSite MapPrivacy PolicyTerms and Conditions
Website Feedback
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

order@acrobiosystems.com

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland